Current location:Home News Information Company news
Conference on "Mycoplasma Pneumonia in Children" in Yangzhou
Release time:

On March 25th, Mole Bioscience and the Pediatric Respiratory Group of the Chinese Maternal and Child Health Association successfully held a conference on "Mycoplasma Pneumonia in Children" in Yangzhou. Pediatric experts from all over the country gathered together to discuss the issue.


During the conference, Professor Chen Zhimin from the Children's Hospital Affiliated to Zhejiang University School of Medicine, Professor Dong Xiaoyan from Shanghai Children's Hospital Affiliated to Shanghai Jiaotong University, and Professor Wang Yingshuo from the Children's Hospital Affiliated to Zhejiang University School of Medicine each gave a special report on the latest research results of Mycoplasma Pneumonia. The three professors pointed out that Mycoplasma Pneumonia (MP) is an important pathogen for community-acquired pneumonia (CAP) in children, and macrolides are the preferred drugs for treating MP infections. However, in recent years, macrolide-resistant Mycoplasma Pneumonia (MRMP) has been continuously emerging and spreading, and infections caused by MRMP can prolong the patient's fever time, antipyretic time, and hospital stay.



The mutation of the 23S rRNA gene locus leads to the production of MRMP, and drug-resistant gene detection can quickly diagnose MRMP early, and the results of drug-resistant gene detection are highly consistent with clinical drug resistance, with good consistency. In addition, timely identification of MRMP and refractory Mycoplasma Pneumonia (RMPP) is also conducive to early and effective treatment, reducing the occurrence of severe and sequelae.


Mole Bioscience's Mycoplasma Pneumoniae and Macrolides-Resistant Strain Nucleic Acid Test Kit (Fluorescent Probe-based real-time PCR assay) uses multiple fluorescent PCR technology to simultaneously detect MP and its macrolide antibiotic-resistant mutation sites, which can quickly diagnose MRMP early and is beneficial to the formulation of patient diagnosis and treatment plans.


In the future, Mole Bioscience will continue to contribute to the development of pediatric medicine and safeguard the health of more children.